About
Radiotherapy
Areas of Focus
Categories
RadiopharmaceuticalsSouthwestern U.S.
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
5
As Collaborator
0
Total Enrollment
193
By Phase
PHASE1: 4PHASE1/PHASE2: 1
By Status
RECRUITING: 3NOT_YET_RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT07061626Lead Sponsor
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
PHASE1Not yet recruiting
56 participants
Started: Sep 30, 2025 · Completed: Mar 31, 2027
NCT07098806Lead Sponsor
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
PHASE1Recruiting
24 participants
Started: Jul 2, 2025 · Completed: Oct 2, 2031
NCT05460507Lead Sponsor
Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
PHASE1Recruiting
40 participants
Started: Dec 12, 2024 · Completed: Mar 1, 2028
NCT05034497Lead Sponsor
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
PHASE1Active, not recruiting
18 participants
Started: Dec 6, 2021 · Completed: Jun 30, 2026
NCT01906385Lead Sponsor
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
PHASE1/PHASE2Recruiting
55 participants
Started: Jun 3, 2015 · Completed: Dec 31, 2025
Locations (1)
Headquarters
Austin, TX, United States
Map
Loading map...